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Abstract: 
Typically Genome-Wide Association Studies (GWASs) perform per-SNP association tests to 
identify variants involved in disease or trait susceptibility. However, such an approach is not 
powerful enough to unravel genes that are not individually contributing to the disease/trait but 
that may play a role in interaction with other genes as a group. Pathway analysis is an 
alternative way to highlight such group of genes. Using SNPs association p-values from 8 
Multiple Sclerosis (MS) GWAS datasets, we performed a candidate pathway analysis for MS 
susceptibility considering genes interacting in cell adhesion molecules (CAMs) biological 
pathway using Cytoscape software. This network is a strong candidate since it is involved in 
the crossing of the blood brain barrier by the T cells, an early event in MS pathophysiology, 
and used as an efficient therapeutic target. We drew up a list of 76 genes belonging to the 
CAMs network. We highlighted 64 networks enriched with CAMs genes with low p-values. 
Filtering by a percentage of CAMs genes up to 50% and rejecting enriched signals mainly 
driven by transcription factors, we highlighted 5 networks associated with MS susceptibility. 
One of them, constituted of ITGAL, ICAM1 and ICAM3 genes could be of interest to develop 
novel therapeutic targets. 
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Introduction 
 Multiple Sclerosis (MS) is a common inflammatory and demyelinating disease of the 
central nervous system 1. Epidemiological studies have proved the multifactorial causes of the 
disease, resulting from the interaction between genetic factors and currently unknown 
environmental factors 2. 
To date, MHC genetic variants, as well as 110 non-MHC variants, have been 
associated with MS susceptibility by GWAS3-7. However, it has been estimated that several 
other genes contribute to disease susceptibility and are yet to be identified8. 
 Several hypotheses have been proposed to explain the missing heritability9,10. One of 
them points at interactions between genes involved in the same biological pathway11, 12. 
According to this hypothesis, some of the genes implicated in MS susceptibility cannot, on 
their own, reach GWAS significance but grouped in a pathway may collectively contribute to 
MS genetic component.  
 The initial event leading to the development of an MS lesion is blood-brain-barrier 
(BBB) disruption and the crossing of the latter by peripherally activated T cells 13. This step, 
which is a key mechanism in our current understanding of MS physiopathology, requires the 
interaction of integrins, cell surface molecules expressed by T cells, to the adhesion molecules 
expressed by the BBB endothelium, ultimately allowing the lymphocytes transmigration into 
the brain14-17. 
 The importance of the BBB crossing in MS physiopathology is stressed by the use of 
treatments active on adhesion molecules. For example, Natalizumab, a monoclonal antibody 
blocking the interaction between VLA-4 (very late antigen-4) molecule (composed of ITGB1, 
integrin beta 1, and ITGA4, integrin alpha 4, integrins subunits) and its receptor VCAM1 
(vascular cell adhesion molecule-1), is among the most efficient therapies available for MS 
patients to date 18, 19. The role of adhesion molecules in MS has also been reinforced by the 
demonstration that the expression of ALCAM (activated leucocyte cell adhesion molecule) 
located at the surface of the BBB endothelium, was increased during the inflammatory 
process in MS patients. In the same study, it has been shown that in vitro expression of 
ALCAM, ICAM-1 (intercellular cell adhesion molecule-1) and VCAM-1 was dependent of 
activation of the human BBB endothelial cells by pro-inflammatory cytokines (TNF, Tumor 
Necrosis Factor et IFN-γ, Interferon-gamma) 20 
 Moreover, genetic studies pointed out the importance of adhesion molecules in the 
susceptibility to the disease21, 22. In 2003, we reported that a rare haplotype of the ICAM-1 
gene (intercellular adhesion molecule 1, expressed at the surface of endothelial cells) was 
 
 
under-transmitted to patients, suggesting a protective effect of this haplotype 21. In 2009, a 
pathway meta-analysis combining two GWAS uncovered genetic variants that interacted in 
the CAM (Cell Adhesion Molecules) pathway potentially contributing to MS development22. 
This new strategy led to the identification of new genes that do not significantly contribute to 
MS susceptibility individually but play an important role in interaction with other genes of the 
biological pathway. An earlier protein interaction network-based pathway analysis (PINBPA) 
considered all the SNPs with a p-value below of 0.05, without any prior analysis on genes 
function. That study showed significant interactions among adhesion molecule-coding genes 
including ICAM-1, ITGB2 (integrin beta 2), ITGAM (integrin alpha M), ITGA6 (integrin 
alpha 6), CD58 (CD58 molecule), CD2 (CD2 molecule) and CD4 (CD4 molecule). This 
observation, coming from a meta-analysis of two independent GWAS, suggests that the 
biological network of adhesion molecules is involved in MS susceptibility.  
In order to decipher the role of the CAMs pathway in MS susceptibility, we conducted 
a candidate pathway analysis (CPA) focusing on adhesion molecules. We found 5 networks of 
the CAMs pathway enriched in low p-values for genes interacting synergistically to confer 
MS susceptibility. 
 
Results 
 CAMs pathway selected genes  
 Using KEGG database and Sabiosciences website, we identified 76 genes of interest 
involved in the adhesion molecule pathway. More than 85% of them (66 out of 76) were 
involved in 3 sub-pathways: Adhesion, Adherens Junctions and Tight Junctions, and 10 
encode for transcription factors highly involved in adhesion molecule genes regulation (see 
Supplementary Table 1). 
 Using data from 8 GWAS studies, we selected calculated p-values of identified CAMs 
genes (+/- 1kb from the 5’ and 3’ UTR). Seven GWAS (IMSGC UK, IMSGC US, ANZGene, 
GeneMSA DU, GeneMSA SW, GeneMSA US and BWH/MIGEN) constituted the D1 
Dataset.4 The 8th GWAS (IMSGC WTCCC2) constituted the D2 dataset 3 (See figure 1). 
70 of the 76 genes were represented by at least one SNP in at least one of the 7 datasets 
included in D1, whereas 68 genes of the 76 were represented by at least one SNP in the 
WTCCC2 dataset (D2 dataset). 6 of the 76 genes of interest were thus excluded from further 
analysis. The number of available SNPs per gene and per dataset is given in Supplementary 
Table 2. D1 and D2 gene-wise p-values, computed using VEGAS software (see Materials and 
Methods section and Figure 1) are given in Table 1. As expected, CD58, NFKB1 and STAT3 
 
 
genes previously identified as associated with MS in GWAS show low gene-wise p-values, 
PD1 = 1.89x10-6, PD2 = 0 (meaning that P<89x10-6, see Materials and Methods section); PD1 = 
0.0125, PD2 = 0.0011; PD1 = 2.94x10-5, PD2 = 1.5x10-5 respectively.  
 Interestingly, VCAM1, previously identified as associated to the disease, with 
rs11581062 being the most statistical significant SNP, did not reach a significant p-value (PD1 
=0.7224; PD2 =0.993) neither in the D1 nor in the D2 datasets. The published associated SNP 
(rs11581062) is 202kb far from VCAM1 gene. We conclude that even if VCAM1 is a good 
candidate gene for MS physiopathology, not enough evidence support its involvement within 
the rs11581062 region. Furthermore, none CIS-e-QTL regulating VCAM1 expression was 
described within the 1 Mb region around the gene (Pritchard lab resources). 
 
 Sub-networks associated with MS susceptibility 
 As described by IMSGC et al. 23, we used a curated human protein interaction network 
(PIN) dataset, consisted in a network of more than 400,000 interactions among ~25,000 
proteins. In order to be confident with the interactions, we selected those quoted  in at least 2 
publications. It results to a reduced human PIN dataset of 8,920 proteins and 27,724 
interactions. Using Cytoscape software, we attributed gene-wise p-values to 70 of the 76 
CAMs genes (listed in Supplementary Table 1). As mentioned in IMSGC et al. 23, Cytoscape 
plugin jActives modules was used to calculate a global score (Z-score) for all the possible 
networks that could be form from the PIN dataset, using D1 and D2 p-values. Networks with 
Z-scores greater than 3.0 are generally considered significant, i.e. these sub-networks are 
enriched in CAMs genes showing D1 and/or D2 gene-wise significant p-values. The 
cytoscape software was applied on the reduced human PIN dataset, containing CAMs genes 
(see supplementary Table 1 and Figure 2) and non-CAMs ones. 64 networks were highlighted 
regarding the enrichment of CAMs genes with significant p-Values. Focusing on the process 
of BBB transmigration by T-cells, we only considered as relevant for our study 6 networks 
with at least 50% of CAMs genes. Finally, we excluded subnets that were only enriched in 
CAMs transcription factors to prevent from non-specific association signal only driven by 
transcription factors (see Table 2 and Figure 2). We identified 5 networks constituted by 
genes known to interact together within the CAMs pathway and meeting all expressed criteria 
(See Figure 3).  
 
Discussion 
 
 
 GWAS and replication studies have successfully identified approximately 110 non-
MHC MS susceptibility genes3-7. However, an important part of genetic heritability remains 
to be discovered3. One of the hypotheses which can be put forward postulates that genes 
without individual effect could influence the susceptibility to the disease through genetic 
interactions 11. Here, we report the first candidate pathway analysis on the Cell Adhesion 
Molecules (CAMs) network in MS. Our results highlight 5 sub-networks enriched in CAMs 
genes with significant p-values, reflecting a potential genetic contribution of these molecules 
in MS susceptibility. 
 In 2009, Baranzini et al. identified 7 genes of the CAMs pathway as associated with 
MS susceptibility considering their interaction22. Focusing on the CAMs pathway and using 
two powerful datasets (5,545+9,772 patients and 12,153+17,376 controls), our study refines 
the role of these genes as MS genetic factors. 
 Two of the 5 identified networks (network 2 and 27) appear to be the highest 
contributors to MS physiopathology. The network 2 is constituted by ICAM1, ICAM3 and 
ITGAL genes that are involved in the adhesion process of the T cells on the endothelial cells 
of the Blood-Brain Barrier (BBB). The adhesion process between endothelial and T cells is 
one of the earliest event in MS development leading to the T cells transmigration into the 
central nervous system across the BBB. Of note, ITGAL, ICAM1 and ICAM3 molecules 
constitute ligand-receptor complexes, ITGAL interacting both with ICAM1 and ICAM3. Our 
hypothesis on the role of these genes in MS susceptibility is that some intra- and inter-gene 
combinations of polymorphisms could influence the adhesion process of T cells on the BBB 
leading to a positive or negative modulation of the inflammatory cells flow into the CNS. 
 The network 27 is constituted by CD82 (KAI1), ITGA4, ITGB1, ITGB2, and HLA-
DMA genes. The ITGB1 and ITGA4 genes code for the two subunits of the VLA4 molecule. 
CD82 is notably known for its inhibitory effect on ITGB1 activation24. The effective role of 
CD82 in inflammatory response has not been yet investigated. In the MS context, it would be 
relevant to analyze the development and the severity of EAE (Experimental Autoimmune 
Encephalomyelitis; MS animal model) in CD82 deficient mice. Since CD82 initiates the 
differentiation of oligodendrocytes precursors into mature myelinating cells25, quantification 
of remyelination in this model would be of interest. 
Interestingly we identified two networks containing the ITGA4 molecule which is the 
target of Natalizumab. The interaction between VLA-4 and his receptor VCAM1 is known to 
be crucial for the transmigration of T cells across the BBB and potentially the molecular basis 
for this treatment’s effectiveness.  
 
 
In conclusion, our results highlighting the role of CAMs genes interactions in MS 
susceptibility could be of high interest to identify new targets for efficient treatments for MS. 
A monoclonal antibody directed against ITGA4 that prevent its interaction with VCAM1 
already exists18. We propose that targeting ITGAL or ICAM1 or ICAM3 in order to block 
their interactions could also be an efficient way to prevent the crossing of the BBB by T cells. 
 
Materials and Methods 
Ethics Statement 
 All the data used in this study have been generated by previous studies 3, 4. Ethics 
approval could be found in the corresponding publications. 
 
Selection of genes coding for CAMs pathway molecules 
 The selection of the genes belonging to the network has been performed in 3 phases: 
Using KEGG (Kyoto Encyclopedia for Genes and Genomes) database 
(http://www.genome.jp/kegg/) 26, 27, we searched for adhesion molecules involved in tight and 
adherens junctions between BBB endothelial cells, and for those involved in T cells 
transmigration. Still Using KEGG database, we then identified molecules interacting directly 
with adhesion molecules. In a last step, we selected the 10 transcription factors that are most 
involved in adhesion molecule-coding genes expression and regulation using the 
SabioSciences website (http://www.sabiosciences.com) through GeneCards database  
(http://www.genecards.org/) 28. Using this 3-step strategy, we compiled a list of 76 genes of 
interest. 
 
Datasets 
 Eight datasets were used in this study. Seven datasets (IMSGC UK, IMSGC US, 
ANZGene, GeneMSA DU, GeneMSA SW, GeneMSA US and BWH/MIGEN) are described 
in Patsopoulos et al and constitute the D1 dataset. 4. The 8th dataset consists in the MS GWAS 
published by the IMSGC and WTCCC2 in 2011 and conbstitute the D2 dataset3. Since the 
IMSGC-WTCCC2 dataset is to date the most powerful GWAS published in MS, we decided 
to use this dataset separately to avoid signals losses.  
 
Statistical analysis 
Gene-wise p-values computation 
 
 
 With data from 8 GWAS we computed an individual gene-wise p-value corresponding 
to the association of each gene with MS in each GWAS using VEGAS software 29 (see Figure 
1) VEGAS assigns SNPs to each of 17,787 autosomal genes according to positions on the 
UCSC Genome Browser (hg18 assembly). For the capture of regulatory regions and SNPs in 
LD, gene boundaries are defined as +/- 50kb of each gene. VEGAS takes into account LD 
patterns between markers within a gene by using Monte-Carlo simulations from the 
multivariate normal distribution on the basis of the LD structure of a set of reference 
individuals (the HapMap2 CEU [Utah residents with ancestry from northern and western 
Europe from the CEPH collection] population). In VEGAS, the number of simulations per 
gene is determined adaptively. In the first stage, 103 simulations are performed. If the 
resulting empirical p value is less than 0.1, 104 simulations are then performed. If the 
empirical p value from 104 simulations is less than 0.001, the program will perform 106 
simulations. At each stage, the simulations are mutually exclusive. For computational reasons, 
if the empirical p value is 0, then no more simulations will be performed. An empirical p 
value of 0 from 106 simulations can be interpreted as p < 10-6, which exceeds a Bonferroni-
corrected threshold of p < 2.8 x 10-6.  
To combine the gene-wise p-values across the seven datasets described above (named D1), 
we applied Fisher’s method for each of the 70 selected genes. The gene-wise p-values from 
the IMSGC-WTCCC2 dataset were used separately, as a second independent dataset (named 
D2) (See Figure 1).   
 
Protein interaction network-based pathway analysis (PINBPA) 
As described by IMSGC et al. in 2013 23, we integrated data from a curated human 
protein interaction network (PIN) dataset in Cytoscape software 30. Cytoscape plugin jActives 
modules was used to calculate a global score for each network enriched in CAMs genes 
showing D1 and/or D2 gene-wise significant p-values. Using successive filters we identified 
networks enriched in low p-Values with at least 50% of CAMs genes and less than 50% of 
transcription factors (See Figure 2).  
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Legend 
 
 
Figure 1. D1 and D2 P-Values computation 
Colored circle represent SNPs. The number of SNPs varies for the different genes (from 1 to 
539, see supplementary table 2) in the different datasets. 
Data from each GWAS are composed by p-value assigned to each SNPs localized within 70 
CAMs genes (gene boundaries +/- 50Kb). 
Dataset-A: GWAS ANZGene; Dataset-B: GWAS BWH/MIGEN; Dataset-C: GWAS MSA 
DU; Dataset-D: GWAS MSA SW; Dataset-E: GWAS MSA US; Dataset-F: GWAS IMSGC 
US; Dataset-G: GWAS IMSGC UK; Dataset-H: GWAS WTCCC2. 
VEGAS Software assigns one gene-wise p-Value to each gene in each GWAS 
Fischer product assigns D1 p-Value to each gene. 
 
Figure 2. Protein interaction network-based pathway analysis 
 
Figure 3. Networks enriched in CAMs genes with significant D1 and/or D2 pvalue 
Each node represents a gene product and each edge, a physical interaction reported in at least 
two independent publications. Each network is enriched with CAMs genes having low p-
values. Nodes are colored according to D1 p-values (red: highly significant, orange: 
moderate, yellow: D1_p-value = 0.05, white: not significant). Analysis was performed using 
Cytoscape and jActive module plugin. 
 
Table 1. D1_ and D2_ Gene-wise p-values. 
D1_Gene-wise p-values have been computed using VEGAS software and fisher product.  
D2_Gene-wise p-values were calculated using VEGAS software only.  
 
Table 2. Selection criteria of the sub-networks 
In red, the 5 selected sub-networks that met the criteria. 
In white, excluded sub-networks with less than 50% of CAMs genes in the sub-network 
In blue, excluded sub-networks with more than 50% of CAMs transcription factors among the 
CAMs genes in the sub-network 
# Genes: Number of genes in the sub-network 
# CAMs Genes: Number of genes of the network that belong to the CAMs genes list 
% CAMs Genes: Ratio (# Genes / # CAMs Genes) 
# CAMs TF: Number of CAMs Transcription factors in the sub-network 
CAMs TF / CAMs Genes: Ratio (# CAMs TF / # CAMs Genes) 
 
Supplementary Table 1. Name, localization and function of selected CAMs pathway 
genes. 
Chr: chromosome 
Start: Starting Chromosomal Position in NCBI B36 
End: Ending Chromosomal Position in NCBI B36 
TJ: Tight Junctions 
 
 
AJ: Adherens Junctions 
TF: Transcription Factors 
 
Supplementary Table 2. Number of genotyped SNPs in each original dataset. 
 
